Evaluating the First-in-Human Clinical Trial of a Human Embryonic Stem Cell-Based Therapy

Kennedy Institute of Ethics Journal 22 (3):243-261 (2012)
  Copy   BIBTEX

Abstract

The transition of novel and potentially promising medical therapies into their initial human clinical trials can engender conflicting pressures. On the one side, because Phase I trials raise greater ethical and human protection challenges than later stage clinical trials, there is a need to proceed cautiously. This is particularly the case for Phase I trials with a novel therapy being tested in humans for the first time, usually termed first-in-human (FIH) trials, especially if the FIH trial involves significant risks. On the other side, scientists interested in having their research validated, corporations with a financial interest in the field, and potential patients and patient support groups desirous of having ..

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 102,020

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Analytics

Added to PP
2012-12-10

Downloads
100 (#213,712)

6 months
11 (#378,953)

Historical graph of downloads
How can I increase my downloads?

References found in this work

No references found.

Add more references